Simple upgrade programs for our latest technology

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
§ Refers to SmartGuard^™ feature. Individual results may vary.
**Fingersticks required in manual mode and to enter SmartGuard^™. If symptoms don’t match alerts and readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard^™.

PROGRAMS TERMS AND CONDITIONS:

1. General Pump Pathway Program

• Customers with more than six months remaining on their pump warranty (or 5-year Medicare guidelines) are eligible for the Pathway Program.
• The Pump Pathway Program is for hardware pump upgrades only.
• A $399 payment will be required upfront to utilize the Pump Pathway Program. The program price includes one (1) insulin pump. CGM products and consumables are not included.
• The Pump Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a pump through this program.
• MiniMed^™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new pump, as it could affect ongoing coverage of their future pump supplies.
• Customers must return their old pump within 30 days. Customers who do not return their pump will be charged $3,200.
• Medicare customers within the 13-month rental period cannot participate in this program.
• Medicare customers will be required to submit an ABN to utilize the Pathway program.
• Customers using Kaiser Permanente Medicaid or Medicare Advantage health plans are excluded from this program.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged pump, the price of the new pump, and the relationship between the parties
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Pricing, terms, and conditions are subject to change at any time and without notice.

2. Switch2System Program

• Customers with more than six months remaining on their competitive pump warranty (or 5-year Medicare guideline) are eligible for the Switch2System Program.
• A $499 payment will be required to use this program. This price includes one (1) insulin pump, one (1) compatible transmitter, one (1) month of consumables and one (1) month of sensors.
• Customers enrolled in federal, state, or government-funded healthcare plans are excluded from receiving a transmitter and sensors from this program and cannot participate in a payment plan.
• An ABN will be required to utilize this program for all Medicare customers.
• Customers may return product that has been shipped as part of this program up to 90 days from the date of shipment.
• Customers must return their competitor pump or receiver within 90 days. Customers who do not return their pump will be charged $4,500.
• This program does not extend the warranty period of the replaced pump. The customer’s current pump warranty timeline will not change by purchasing a pump through this program.
• Customers should verify that their insurance provider will support transitioning to the new pump, as it could affect ongoing coverage of their future pump supplies.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• MiniMed™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• A valid prescription will be required to purchase a pump, CGM and supplies. Other restrictions may apply.
• Medicare customers within a 13-month rental period cannot participate in this program.
• Customers using Kaiser health plans are excluded from this program.
• Pricing, terms, and conditions are subject to change at any time and without notice.

3. Medtronic Pump Trade-in Program

• This program is available for out-of-warranty MiniMed^™ insulin pump customers as well as out-of-warranty competitor pump customers.
• A sales credit may be applied to orders where a customer is upgrading from an older model pump to a newer model pump through insurance.
• Customers may receive a $500 credit for trading in a MiniMed^™, Tandem®, Animas®, or Roche® pump. Customers may receive a $250 credit for trading in a Omnipod® receiver.
• Customers must return their old pump within 30 days. Failure to return your old pump will disqualify you for the Pump Trade-in Program credit, and you will be responsible for the full estimated cost of the Medtronic pump system being purchased.
• MiniMed^™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider regarding indications for use.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Pricing, terms, and conditions are subject to change at any time and without notice.

5. MiniMed^™ 770G Pump Software Upgrade Program

• This program allows in-warranty MiniMed^™ 770G pump users a software upgrade to the MiniMed^™ 780G pump at no charge.
• The process may result in healthcare provider office visit and may result in the out-of-pocket expenses such as co-pay, depending on insurance coverage.
• This program includes the insulin pump software only. CGM products and consumables are not included in this offer.
• Warranty dates do not reset. The replacement warranty date of an insulin pump upgraded with the software will remain the same as the replacement warranty date of the initial pump purchased.
• MiniMed^™ pumps and software have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider regarding your eligibility to receive the software upgrade based on the labeling of the upgrade, which may differ from the labeling of the MiniMed^™ 770G pump
• Insurance coverage and plan design varies and may impact the ability to upgrade. Coverage is contingent upon your health insurance medical policy guidelines. Restrictions and medical necessity requirements may apply
• A valid prescription will be required for this software upgrade. All participants should consult their healthcare provider for all therapy-related decisions.
• Software upgrade may require the completion of product related training.
• Program terms and conditions are subject to change at any time and without notice. Other restrictions may apply.

6. General Continuous Glucose Monitor (CGM) Pathway program for 600 series users

• The Continuous Glucose Monitor (CGM) Pathway Program is for CGM customers who are using a MiniMed^™ 630G or MiniMed^™ 670G pump only. CGM supplies and consumables are not included.
• Customer must have an in-warranty transmitter to participate in the CGM Pathway Program.
• This program is available to customers whose payers bill transmitters and sensors separately. Customers whose payers utilize a monthly CGM supply allowance are excluded from this program.
• Customers transitioning from one Medtronic CGM system will not have any upfront out-of-pocket costs to Pathway to another Medtronic CGM transmitter.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current pump system.
• The CGM Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a CGM through this program.
• MiniMed^™ CGM’s have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Heathcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new CGM, as it could affect ongoing coverage to future CGM supplies.
• Customers must return their old transmitter within 30 days. Customers who do not return their CGM will be charged $200.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged CGM, the prices of a new CGM, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to obtain a new CGM. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.

7. Guardian^™ Connect System Smart Step Pathway Program

• The Guardian^™ Connect System Smart Step Pathway Program is for Standalone Guardian^™ Connect System customers transitioning to a Medtronic sensor-augmented insulin pump system only. CGM supplies and consumables are not included.
• Customers must have an in-warranty transmitter to participate in the Guardian^™ Connect System Smart Step Pathway Program.
• This program is available to customers who have insurance coverage for the Guardian^™ Connect System.
• Customers transitioning from one Medtronic CGM system will not have any upfront out-of-pocket costs to Pathway to another Medtronic CGM transmitter.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current pump system.
• The Guardian^™ Connect System Smart Step Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a CGM through this program.
• MiniMed^™ CGM’s have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Heathcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new CGM, as it could affect ongoing coverage of their future CGM supplies.
• Customers must return their old CGM within 30 days. Customers who do not reutn their CGM will be charged $200.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged CGM, the price of the new CGM, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to the federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available any information that Medtronic pay provide concerning the discount.
• A valid prescription will be required to obtain a new CGM. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.

8. Continuous Glucose Monitor (CGM) Supply Allowance Process

• The Continuous Glucose Monitor (CGM) Supply Allowance Process is for CGM upgrades only. CGM supplies are included as prescribed.
• Customers transitioning from one CGM system will not have any upfront out-of-pocket transmitter cost for the opportunity to transition to another CGM transmitter.
• Applicable out-of-pocket CGM supply costs will apply.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current pump system along with their monthly one (1) 5-pack of compatible sensors and other CGM supplies as prescribed.
• This process is available to customers whose payers utilize a monthly CGM supply allowance. Customers with insurance providers that bill transmitters and sensors separately are excluded from this process.

Important Safety Information: MiniMed^™ 780G System With SmartGuard^™ Technology With Guardian^™ 4 Sensor
The MiniMed^™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 780G system includes SmartGuard^™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed^™ 780G system consists of the following devices: MiniMed^™ 780G insulin pump, the Guardian^™ 4 transmitter, the Guardian^™ 4 sensor, One-press serter, the Accu-Chek^™ Guide Link blood glucose meter, and the Accu-Chek^™ Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian^™ 4 sensor is intended for use with the MiniMed^™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian^™ 4 sensor is indicated for up to seven days of continuous use.

The Guardian^™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed^™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian^™ 4 sensor. The Guardian^™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian^™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard^™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard^™ feature.

WARNING: Do not use the MiniMed^™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard^™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed^™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Important Safety Information: MiniMed^™ 770G System With SmartGuard^™ Technology
The MiniMed^™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 770G System includes SmartGuard^™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed^™ 770G System consists of the following devices: MiniMed^™ 770G Insulin Pump, the Guardian^™ Link (3) Transmitter, the Guardian^™ Sensor (3), one-press serter, the Accu-Chek^® Guide Link blood glucose meter, and the Accu-Chek^® Guide Test Strips. The system requires a prescription.

The Guardian^™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian^™ Sensor (3).

All therapy adjustments should be based on measurements obtained using the Accu-Chek^® Guide Link blood glucose meter and not on values provided by the Guardian^™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek^® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.

WARNING: Do not use the SmartGuard^™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard^™ Auto Mode.

WARNING: Do not use the MiniMed^™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 770G system.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed^™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Important Safety Information: MiniMed^™ 670G System
The Medtronic MiniMed^™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 670G system includes SmartGuard^™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian^™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR^®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR^®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian^™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR^®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed^™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Important Safety Information: Guardian^™ Connect CGM System
The Guardian^™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide and important safety information.